untitled design

COVID-19: AstraZeneca antibody drug offers 83% protection over six months

AstraZeneca announced today that its anti-COVID-19 antibody drug was 83% effective in reducing the risk of developing a symptomatic disease over a six-month period, according to a follow-up test.

This treatment, given in injectable form and called AZD7442 or Evusheld, had previously been shown to provide 77% protection against symptomatic disease after three months, in a previous display of the results of the PROVENT final stage test in August.

The British-Swedish company also reported that a separate trial, conducted in patients with mild to moderate COVID-19, showed that a higher dose of AZD7442 reduced the risk of worsening symptoms by 88% when given within three days of the onset of symptoms. .

“These new data add to the growing body of evidence supporting AZD7442’s ability to make a significant difference in the prevention and treatment of COVID-19,” said Mene Pangalos, the company’s executive vice president.

Source: AMPE

.

Source From: Capital

You may also like

Get the latest

Stay Informed: Get the Latest Updates and Insights

 

Most popular